查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1729530

日本特发性肺纤维化治疗市场报告（按药物类别（MAPK 抑制剂、酪胺酸抑制剂、自分泌运动因子抑制剂）、最终用户（医院、长期照护机构等）和地区划分）2025 年至 2033 年

Japan Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 118 Pages | 商品交期: 5-7个工作天内

价格

2024年，日本特发性肺纤维化治疗市场规模达1.81亿美元。展望未来， IMARC Group预计到2033年市场规模将达到3.45亿美元，2025-2033年期间的成长率（CAGR）为7.4%。

特发性肺纤维化 (IPF) 是一种慢性间质性肺炎，其特征是肺组织增厚和疤痕形成。 IPF的临床症状包括呼吸困难、持续干咳、疲劳、食慾不振和四肢肿胀。透过血液检查、胸部X光检查、电脑断层扫描 (CT)、肺部活检和肺功能测试进行诊断。特发性肺纤维化 (IPF) 的治疗方法是使用抗纤维化药物，这种药物可以减缓疤痕组织的形成速度并控制与疾病相关的症状。也提供支持性治疗方案，包括肺部復健、安宁疗护和补充氧气疗法，作为 IPF 的有效治疗计划。

日本特发性肺纤维化治疗市场趋势：

纤维化疾病的盛行率不断上升，尤其是在老年人群中，这主要推动了日本特发性肺纤维化治疗市场的成长。这可以归因于尼古丁产品消费量的增加、污染水平的激增以及压力水平的上升。除此之外，健康意识的增强以及对特发性肺纤维化 (IPF) 有效预防和管理策略的认识的提高也是促进成长的因素。其他因素，例如引入新疗法的广泛研究和开发 (R&D) 活动以及现有医疗保健基础设施的进步，正在对全国市场的成长产生积极影响。

本报告回答的关键问题：

  • 日本特发性肺纤维化治疗市场目前表现如何，未来几年又会如何表现？
  • COVID-19 对日本特发性肺纤维化治疗市场有何影响？
  • 主要的区域市场有哪些？
  • 根据药品类别，市场是如何分類的？
  • 根据最终用户，市场是如何分類的？
  • 该产业的价值链分为哪些阶段？
  • 该行业的主要驱动因素和挑战是什么？
  • 日本特发性肺纤维化治疗市场的结构是怎么样的？主要参与者有哪些？
  • 产业竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：日本特发性肺纤维化治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药品类别

  • MAPK抑制剂
  • 酪胺酸抑制剂
  • 自分泌运动因子抑制剂

第七章：市场区隔：依最终用户

  • 医院
  • 长期照护机构
  • 其他的

第 8 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第九章：价值链分析

第 10 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 11 章：价格分析

第 12 章：政策与监管格局

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
Product Code: SR112025A5479

The Japan idiopathic pulmonary fibrosis treatment market size reached USD 181.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 345.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.4% during 2025-2033.

Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial pneumonia characterized by the thickening and scarring of lung tissue. The clinical symptoms of IPF include breathing difficulties, persistent dry cough, fatigue, loss of appetite, and swollen limbs. It is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs, which slows the rate at which the scar tissues are formed and controls the symptoms associated with the disease. Supportive therapeutic options, including pulmonary rehabilitation, palliative care, and supplemental oxygen therapy, are also provided as the effective treatment plan for IPF.

Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the IPF treatment market growth across Japan. This can be attributed to a rise in the consumption of nicotine-based products, a surge in pollution levels, and rising stress levels. Other than this, increasing health consciousness and rising awareness regarding the effective prevention and management strategies of IPF are acting as growth-inducing factors. Other factors, such as extensive research and development (R&D) activities for introducing novel therapies, and advancements in the existing healthcare infrastructure, are positively influencing the market growth across the country.

Key Market Segmentation:

Breakup by Drug Class:

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors

Breakup by End User:

  • Hospitals
  • Long-term Care Facilities
  • Others

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Key Questions Answered in This Report:

  • How has the Japan idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan idiopathic pulmonary fibrosis treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the Japan idiopathic pulmonary fibrosis treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Japan Idiopathic Pulmonary Fibrosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 MAPK Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Tyrosine Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Autotaxin Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Long-term Care Facilities
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Policy and Regulatory Landscape

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players

List of Figures

  • Figure 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
  • Figure 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
  • Figure 6: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2024
  • Figure 7: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
  • Figure 20: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
  • Figure 21: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
  • Table 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players